Decreased Expression of NUSAP1 Predicts Poor Overall Survival in Cervical Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Apr 1

PMID 32226503

Citations 19

Authors

Qiqi Xie

Wen Ou-Yang

Mingwei Zhang

Huimei Wang

Qiuyuan Yue

Affiliations

Soon will be listed here.

Abstract

Nucleolar and spindle-associated protein 1 (NUSAP1) was previously reported to be associated with poor prognosis in multiple cancers. In the present study, we comprehensively investigated the clinicopathological features and potential prognostic value of NUSAP1 in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). The expression profiles of the genes were extracted from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), Cancer Cell Line Encyclopedia (CCLE), Gene Expression Profiling Interactive Analysis (GEPIA), and The Human Protein Atlas databases. The association between clinicopathological characteristics and NUSAP1 was analyzed using logistic regression in TCGA patients and receiver operating characteristic (ROC) curve analysis for GSE7803, GSE9750, and GSE63514 datasets. The prognostic value of NUSAP1 in TCGA patients was evaluated using the Kaplan-Meier method and Cox regression. Gene set enrichment analysis (GSEA) was conducted using TCGA dataset. A total of 68 differentially expressed genes (DEGs) were identified in CESC. ROC analysis of NUSAP1 suggested that the area under the ROC curve was 0.968. Kaplan-Meier survival analysis indicated that CESC with low expression of NUSAP1 has a worse prognosis than CESC with high NUSAP1 expression (P = 0.005). The logistic regression revealed that low NUSAP1 expression in CESC was related to advanced tumor stage in TCGA database. Moreover, Cox regression analysis showed that NUSAP1 expression correlated significantly with prognosis in the case of patients in TCGA database. GSEA demonstrated that CESC patients with high expression of NUSAP1 were enriched in the G2M checkpoint, MYC targets, and breast cancer ZNF217. The results suggest that identification of DEGs might enhance our understanding of the causes and molecular mechanisms underlying the development of CESC. Moreover, NUSAP1 may play an important role in CESC progression and prognosis and may serve as a valuable indicator of poor survival in CESC.

Citing Articles

NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target.

Zhang S, Zhang X, Huang W, Jiang G, Mo Y, Wei L Int J Biol Sci. 2024; 20(13):5375-5395.

PMID: 39430250 PMC: 11489181. DOI: 10.7150/ijbs.100188.

Immunotherapeutic value of NUSAP1 associated with bladder cancer through a comprehensive analysis of 33 human cancer cases.

Wen X, Hou J, Chu Y, Liao G, Wu G, Fang S Am J Cancer Res. 2024; 14(3):959-978.

PMID: 38590423 PMC: 10998758. DOI: 10.62347/BGAE1505.

ZNF695, A Potential Prognostic Biomarker, Correlates with Im mune Infiltrates in Cervical Squamous Cell Carcinoma and Endoce rvical Adenocarcinoma: Bioinformatic Analysis and Experimental Verification.

Ding X, Wan A, Qi X, Jiang K, Liu Z, Chen B Curr Gene Ther. 2024; 24(5):441-452.

PMID: 38441026 DOI: 10.2174/0115665232285216240228071244.

Integrated analysis of the potential roles of microRNA-messenger RNA networks in prostate adenocarcinoma.

Zhang N, Jin J, Ye X Heliyon. 2023; 9(12):e22383.

PMID: 38076048 PMC: 10709018. DOI: 10.1016/j.heliyon.2023.e22383.

Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response.

Zheng H, Wang M, Zhang S, Hu D, Yang Q, Chen M Int J Biol Sci. 2023; 19(14):4689-4708.

PMID: 37781040 PMC: 10535697. DOI: 10.7150/ijbs.80017.

References

Ribbeck K, Groen A, Santarella R, Bohnsack M, Raemaekers T, Kocher T . NuSAP, a mitotic RanGTP target that stabilizes and cross-links microtubules. Mol Biol Cell. 2006; 17(6):2646-60. PMC: 1474800. DOI: 10.1091/mbc.e05-12-1178. View

Gordon C, Gulzar Z, Brooks J . NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells. Prostate. 2015; 75(5):517-26. DOI: 10.1002/pros.22938. View

Dehn D, Torkko K, Shroyer K . Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer. 2007; 111(1):1-14. DOI: 10.1002/cncr.22425. View

Li P, Maines-Bandiera S, Kuo W, Guan Y, Sun Y, Hills M . Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer. 2007; 120(9):1863-73. DOI: 10.1002/ijc.22300. View

Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry J . Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-9. PMC: 3037419. DOI: 10.1038/75556. View

Barrett T, Wilhite S, Ledoux P, Evangelista C, Kim I, Tomashevsky M . NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2012; 41(Database issue):D991-5. PMC: 3531084. DOI: 10.1093/nar/gks1193. View

Heintz A, Odicino F, Maisonneuve P, Quinn M, Benedet J, Creasman W . Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S145-60. DOI: 10.1016/S0020-7292(06)60032-5. View

Espinosa A, Alfaro A, Roman-Basaure E, Guardado-Estrada M, Palma I, Serralde C . Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One. 2013; 8(2):e55975. PMC: 3566100. DOI: 10.1371/journal.pone.0055975. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

10.

Zhu X, Lv J, Yu L, Zhu X, Wu J, Zou S . Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol. 2008; 112(1):248-56. DOI: 10.1016/j.ygyno.2008.09.045. View

11.

Wang I, Chou S, Lin Y . Zoledronic acid induces apoptosis and autophagy in cervical cancer cells. Tumour Biol. 2014; 35(12):11913-20. DOI: 10.1007/s13277-014-2460-5. View

12.

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

13.

Colak D, Nofal A, AlBakheet A, Nirmal M, Jeprel H, Eldali A . Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One. 2013; 8(5):e63204. PMC: 3660335. DOI: 10.1371/journal.pone.0063204. View

14.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N . Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv262. DOI: 10.1093/annonc/mdy160. View

15.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

16.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

17.

Krig S, Miller J, Frietze S, Beckett L, Neve R, Farnham P . ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene. 2010; 29(40):5500-10. PMC: 4256946. DOI: 10.1038/onc.2010.289. View

18.

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

19.

Ponten F, Jirstrom K, Uhlen M . The Human Protein Atlas--a tool for pathology. J Pathol. 2008; 216(4):387-93. DOI: 10.1002/path.2440. View

20.

Gautier L, Cope L, Bolstad B, Irizarry R . affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307-15. DOI: 10.1093/bioinformatics/btg405. View